Jan 30, 2019 | News, Uncategorized
Amylon appoints Art Levin to supervisory board; expands scientific advisory board Cambridge, Massachusetts, January 17th 2019 Amylon Therapeutics, a biotechnology company using RNA modulation to target neurological disorders, announces the appointment of Art Levin as...
Jan 10, 2019 | News, Uncategorized
Amylon Therapeutics Targeting central Nervous System Disorders Wins Startup Slam Competition at BIO-Europe® Berlin Eight short-listed life sciences startups pitched to expert panel of judges at fourth Startup Slam competition at BIO-Europe® 2017 Startup Slam sponsor...
Jan 10, 2019 | News, Uncategorized
Amylon Therapeutics announces seed investment round, focus on CNS disorders Key updates Amylon Therapeutics B.V. is a spin-off company from ProQR Therapeutics N.V., a NASDAQ listed biopharmaceutical company based in Leiden, the Netherlands. Amylon announces the...
Recent Comments